Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Apr 2019 Last checked against ClinicalTrials.gov record.
- 05 Apr 2019 Planned primary completion date changed from 18 Jul 2019 to 18 Dec 2020.
- 24 Mar 2017 New trial record